Open AccessPhase I study of antilipopolysaccharide human monoclonal antibody MAB-T88
Author(s) -
Richard Daifuku,
Kathy Haenftling,
John Young,
Eric Groves,
Corinne Turrell,
Frederick J. Meyers
Publication year - 1992
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.36.10.2349
Subject(s) - monoclonal antibody , antibody , monoclonal , immunology , immunotherapy , medicine , virology , immune system
Monoclonal antibody MAB-T88 is a human monoclonal immunoglobulin M antibody directed at the lipopolysaccharide of gram-negative bacteria. In this study, nine patients who were expected to become neutropenic from antineoplastic chemotherapy received an infusion of MAB-T88, three patients at each of three doses: 1, 4, and 8 mg/kg of body weight. MAB-T88 was shown to be safe, with an effective half-life in plasma of 25.4 h, and no patient developed immunoglobulin G antibody to MAB-T88.